0
     

Report Added
Report already added
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Vascular Endothelial Growth Factor B - Drugs In Development, 2022, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 1 respectively. Report covers products from therapy areas Oncology, Ophthalmology and Metabolic Disorders which include indications Metastatic Colorectal Cancer, Colorectal Cancer, Diabetic Macular Edema, Diabetic Nephropathy, Lipid Disorders, Macular Degeneration, Macular Edema, Non-Proliferative Diabetic Retinopathy (NPDR), Retinopathy, Solid Tumor, Uveal Melanoma and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
Alvotech ehf
CSL Ltd
GlycoNex Inc
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Panolos Bioscience
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Rophibio Inc
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
CSL-346 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-101 - Drug Profile
Product Description
Mechanism Of Action
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
Featured News & Press Releases
Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia
Mar 24, 2014: NICE rejects life-extending bowel cancer drug two weeks after Scottish approval
Sep 15, 2013: Approved cancer drug potentially could help treat diabetes, researchers find
Jun 20, 2013: NICE Turns Down Sanofi's Zaltrap For Treatment Of Metastatic Colorectal Cancer
Feb 05, 2013: Sanofi And Regeneron Pharma Receive EU Approval For Zaltrap For Patients With Previously Treated Metastatic Colorectal Cancer
Nov 16, 2012: Sanofi And Regeneron Pharma Announce CHMP Positive Opinion For Zaltrap For Previously Treated Metastatic Colorectal Cancer
Nov 08, 2012: Sanofi Offers Discount On Cancer Drug Zaltrap
Oct 08, 2012: Sanofi Announces Publication Of Phase III Results Of Zaltrap Study In Previously Treated Metastatic Colorectal Cancer Patients In Journal Of Clinical Oncology
Sep 07, 2012: Georgia Health Clinician Studies Zaltrap’s Ability To Prolongs Survival In Patients With Metastatic Colon Cancer
Aug 03, 2012: FDA Approves ZALTRAP After Priority Review For Previously Treated Metastatic Colorectal Cancer
May 16, 2012: Sanofi To Present Data On Zaltrap At American Society Of Clinical Oncology Annual Meeting
Apr 05, 2012: Sanofi And Regeneron Announce ZALTRAP Phase III Study In Prostate Cancer Did Not Meet Primary Endpoint
Apr 05, 2012: Sanofi And Regeneron Receive FDA Priority Review For ZALTRAP Combination Chemotherapy
Sep 23, 2011: Regeneron Announces ZALTRAP Clinical Presentation At EMCC, Sweden
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Alvotech ehf, 2022
Pipeline by CSL Ltd, 2022
Pipeline by GlycoNex Inc, 2022
Pipeline by Luye Pharma Group Ltd, 2022
Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022
Pipeline by Panolos Bioscience, 2022
Pipeline by Prestige BioPharma Ltd, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Rophibio Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F